CD44 and acute myeloid leukemia: RG7356, a recombinant anti-CD44 IgG1 humanized monoclonal antibody, has been administered to 44 patients with refractory/relapsed AML or patients not eligible for intensive chemotherapy in a phase I dose-escalation study [119].